| Autor: |
Saran Maneesuwansin, M.D., Chalairat Suk-ouichai, M.D., Patkawat Ramart, M.D., Siros Jitpraphai, M.D., Kittipong Phinthusophon, M.D., Ekkarin Chotikawanich, M.D., Teerapon Amornvesukit, M.D., Tawatchai Taweemonkongsap, M.D., Bansithi Chaiyaprasithi, M.D., Sunai Leewansangtong, M.D., Sittiporn Srinualnad, M.D., Chaiyong Nualyong, M.D. |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Siriraj Medical Journal, Vol 71, Iss 1, Pp 31-37 (2019) |
| Druh dokumentu: |
article |
| ISSN: |
2228-8082 |
| DOI: |
10.33192/Smj.2019.06 |
| Popis: |
Objective: To evaluate the effects of renin-angiotensin system inhibitors (RASIs) on tumor-recurrence and disease-progression in non-muscle invasive bladder cancer (NMIBC) patients. Methods: From 2006-2015, 348 NMIBC patients at Siriraj Hospital were recruited for this study. Tumor-recurrence was identified after the transurethral resection of bladder cancer (TUR-BT) and pathological confirmation of NMIBC, while stage-progression was defined as muscularis-propria invasion after pathological review or metastases. Cox proportional hazards models were used to assess the recurrence-free survival (RFS) and progression-free survival (PFS) rates. Results: Of the 348 patients, 86 (24.7%) received RASIs at the first TUR-BT. The median age was 68 years, and it was significantly older for the RASI cohort. No differences in the tumor characteristics of the groups were found. The median follow-up periods for tumor-recurrence and stage-progression were 2.3 and 3.7 years, respectively. Forty percent of the patients experienced tumor-recurrence, with the no-RASI cohort experiencing a significantly higher tumor-recurrence rate (46% versus 22%, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
